In the high-stakes world of biopharmaceutical manufacturing, the term "technology transfer" often conjures images of seamless data migration, standardized protocols, and digitized batch records. Yet, beneath the surface of these regulated processes lies a pervasive, often invisible, threat to drug quality and development timelines: the erosion of tacit knowledge.
As the industry pivots toward complex advanced modalities—specifically cell and gene therapies—the loss of this "unwritten expertise" during handoffs between R&D, pilot plants, and contract development and manufacturing organizations (CDMOs) has become a critical operational bottleneck. With over 86% of biopharma companies now relying on outsourcing to manage risk and accelerate timelines, the systemic failure to capture the nuanced "know-how" of scientists and engineers is costing the industry hundreds of millions of dollars annually.
The Nature of the Knowledge Gap
At its core, technology transfer is designed to move documented processes from one environment to another. However, as Ryan Chen, Director of Product Marketing at ValGenesis, observes, "Technology transfer occurs repeatedly across the lifecycle: from CMC development to first GMP clinical supply, and further down to commercial scale, between manufacturing sites and even post-approval when capacity, network or process/method changes are required."
The problem is that the documentation required by regulatory bodies is often a poor proxy for the actual scientific process. Tacit knowledge—the intuition gained through years of experimentation, the "feel" of a bioreactor, or the subtle adjustments made during a failed trial—is rarely captured in Standard Operating Procedures (SOPs). When a scientist leaves a company or a CDMO undergoes a restructuring, this knowledge evaporates, leaving the next team to "reinvent the wheel" or, worse, repeat the mistakes of the past.
A Chronology of Erosion: From Lab Bench to Market
The lifecycle of a drug is a journey through increasingly rigid environments, each acting as a potential filter that strips away valuable context.
The Academic-to-Industry Phase
The decline begins at the point of origin. Academic research is designed for discovery, not scalability. It is inherently flexible, exploratory, and largely undocumented in terms of "failure logs." When a startup spins out of an academic lab, they bring with them intellectual property and proof-of-concept data, but they lack the standardized, scalable systems required for GMP compliance. Patents capture the "what," but they are silent on the "how"—the specific environmental conditions and failed attempts that ultimately led to the successful outcome.
The CDMO Hand-off
As the candidate moves into clinical trials, the reliance on external partners increases. In the current economic climate, where layoffs in manufacturing and CDMO functions rose by 16% in 2025, the risk is amplified. When a CDMO experiences staff turnover, the human vessel for tacit knowledge is removed. Without a robust knowledge management framework, the new team inherits only the cold data of previous batches, lacking the context of why certain process parameters were set in the first place.
The Commercialization Hurdle
Post-approval, the stakes shift to comparability. As companies look to expand their manufacturing networks or adjust processes for global demand, they must prove that the product remains unchanged. This requires deep historical knowledge of the process’s "design space." Without a clear record of the expert decisions made during early development, companies struggle to justify changes to regulators, leading to delays and potential product inconsistency.
Supporting Data: The Financial and Operational Toll
The industry is beginning to quantify what it has long suspected: knowledge management is not just a "nice-to-have" compliance measure; it is a primary driver of financial performance. Merck, for example, attributed a staggering $125 million in value to knowledge management initiatives over a ten-year period. This figure highlights that when knowledge is retained, it optimizes yields, reduces deviations, and slashes the time required for technology transfer.
However, the current landscape remains daunting. Demographic shifts are accelerating the brain drain. With approximately 11,000 baby boomers reaching retirement age every day in the United States, the industry is losing a generation of process engineers and scientists who possess the "tribal knowledge" that simply cannot be digitized by current systems.
Furthermore, the industry’s document-centric regulatory culture often exacerbates the issue. While the International Society for Pharmaceutical Engineering (ISPE) has published a "Good Practice Guide on Knowledge Management in the Pharmaceutical Industry," and the Parenteral Drug Association (PDA) has issued Technical Report No. 65, these are recommendations, not mandates. There is no unified regulatory framework that forces companies to capture the "tacit" elements of their processes. Consequently, many firms prioritize the minimum documentation necessary to pass an audit, leaving the critical scientific context behind.
Advanced Modalities: Why Cell and Gene Therapies Raise the Stakes
The rise of cell and gene therapies (CGT) has shifted the industry from "process is the product" to a paradigm where "operator is the process."
In traditional small-molecule manufacturing, chemical synthesis is highly automated and predictable. In contrast, CAR-T cell manufacturing is a biological, highly variable process. As Ryan Chen notes, "Advanced modalities introduce greater biological variability, complex potency assays, aseptic processing requirements, and sensitivity to operator technique, making transfers more technically demanding."
Because living cells cannot be terminally sterilized, the process itself must be pristine, and the operator’s technique becomes a critical variable in the quality of the final drug product. Subtle variations in how a technician handles cell isolation, expansion, or harvesting can lead to significant swings in product yield and efficacy. Even the interpretation of flow cytometry data—a common QC assay—can vary between operators. When this human element is not properly trained, documented, or transferred through structured knowledge management, the risk of batch failure rises exponentially.
Strategic Responses and Industry Implications
To combat this trend, industry leaders are advocating for a fundamental shift in how technology transfer is perceived. It is no longer an "end-of-development" operational task; it must be a "design-for-transfer" strategy implemented from the very beginning.
Institutionalizing Knowledge Management
Companies are moving toward integrated Quality Management Systems (QMS) that prioritize knowledge retention. This includes the use of digital twins, video-based training modules, and structured "lessons learned" databases that archive not just successful results, but the failed experiments that define the boundaries of the process.
Analytical Readiness
Investment in analytical readiness is paramount. By developing robust, standardized assays that are less reliant on subjective operator interpretation, companies can reduce the "human noise" in their data. This involves selecting CDMO partners that don’t just provide "capacity," but offer deep, modality-specific expertise and a proven track record of successful tech transfer governance.
Governance and Change Control
"Founders can mitigate these risks by designing for transfer early, institutionalizing knowledge management, and embedding strong governance and change-control discipline from the outset," says Chen. This governance must extend across the entire manufacturing network, ensuring that jurisdictional differences and supply chain variables are accounted for before the first batch is produced.
The Path Forward: Moving Beyond Compliance
The loss of tacit knowledge is a quiet, ongoing failure that directly impacts patient outcomes. When technology transfer is incomplete, the result is often higher costs, longer timelines, and a diminished ability to innovate.
For the biopharma industry, the challenge is clear: it must transition from a culture that views documentation as a regulatory hurdle to one that views knowledge management as a core intellectual asset. As we enter an era of increasingly personalized and complex medicine, the companies that succeed will be those that realize that the most valuable part of their process isn’t just the formula in the patent—it’s the accumulated wisdom of the scientists who brought it to life.
By embedding knowledge management into the digital fabric of the organization—from the earliest research bench to the final commercial fill-finish—the industry can ensure that when people move, their expertise stays, and the progress of life-saving therapies continues uninterrupted.
About the Author
